Skip to content

Bladder Cancer Health Center

Medical Reference Related to Bladder Cancer

  1. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview

    Information about the treatment of urethral cancer and the outcomes of therapy is derived from retrospective, single-center case series and represents a very low level of evidence of 3iiiDiv. The majority of this information comes from the small numbers of cases accumulated over many decades at major academic centers. Therefore, the treatment in these reports is usually not standardized and the treatment also spans eras of shifting supportive care practices. Because of the rarity of urethral cancer, its treatment may also reflect extrapolation from the management of other urothelial malignancies, such as bladder cancer in the case of transitional cancers, and anal cancer in the case of squamous cell carcinomas. Role of SurgerySurgery is the mainstay of therapy for urethral cancers in both women and men.[Level of evidence: 3iiiDiv] The surgical approach depends on tumor stage and anatomic location, and tumor grade plays a less important role in treatment decisions.[1,2] Although the

  2. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Bladder Cancer

    Recurrent bladder cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the bladder or in other parts of the body.

  3. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Bladder Cancer

    More than 90% of bladder carcinomas are transitional cell carcinomas derived from the uroepithelium. About 2% to 7% are squamous cell carcinomas, and 2% are adenocarcinomas.[1] Adenocarcinomas may be of urachal origin or nonurachal origin; the latter type is generally thought to arise from metaplasia of chronically irritated transitional epithelium. Small cell carcinomas also may develop in the bladder.[2,3] Sarcomas of the bladder are very rare. Pathologic grade of transitional cell carcinomas, which is based on cellular atypia, nuclear abnormalities, and the number of mitotic figures, is of great prognostic importance.References: Al-Ahmadie H, Lin O, Reuter VE: Pathology and cytology of tumors of the urinary tract. In: Scardino PT, Linehan WM, Zelefsky MJ, et al., eds.: Comprehensive Textbook of Genitourinary Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2011, pp 295-316. Koay EJ, Teh BS, Paulino AC, et al.: A Surveillance, Epidemiology, and End Results analysis

  4. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Bladder Cancer Treatment

    The prognosis for any patient with progressive or recurrent invasive bladder cancer is generally poor. Management of recurrence depends on previous therapy, sites of recurrence, and individual patient considerations. Treatment of new superficial or locally invasive tumors that develop in the setting of previous conservative therapy for superficial bladder neoplasia has been discussed earlier in this summary.Recurrent or progressive disease in distant sites or after definitive local therapy has an extremely poor prognosis, and clinical trials should be considered whenever possible. Patients who have not received previous chemotherapy for urothelial carcinoma should be considered for chemotherapy as described above for stage IV disease. Palliative radiation therapy should be considered for patients with symptomatic tumors.Standard Treatment Options for Recurrent Bladder CancerStandard treatment options for patients with recurrent bladder cancer include the following:Combination

  5. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Bladder Cancer

    Treatment of recurrent bladder cancer depends on previous treatment and where the cancer has recurred. Treatment for recurrent bladder cancer may include the following: Surgery.Chemotherapy.Radiation therapy.A clinical trial of chemotherapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent bladder cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.

  6. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Proximal Urethral Cancer

    Female Proximal Urethral CancerLesions of the proximal or entire length of the urethra are usually associated with invasion and a high incidence of pelvic nodal metastases. The prospects for cure are limited except in the case of small tumors. The best results have been achieved with exenterative surgery and urinary diversion with 5-year survival rates ranging from 10% to 20%. To increase the resectability rate of gross tumor and decrease local recurrence, in an effort to shrink tumor margins, it is reasonable to recommend adjunctive, preoperative, radiation therapy. Pelvic lymphadenectomy is performed concomitantly. Ipsilateral inguinal node dissection is indicated only if biopsy specimens of ipsilateral palpable adenopathy are positive on frozen section. For tumors that do not exceed 2 cm in greatest dimension, radiation alone, nonexenterative surgery alone, or a combination of the two may be sufficient to provide an excellent outcome.It is reasonable to consider removal of part of

  7. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062908-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Bladder Cancer Treatment

  8. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage 0 Bladder Cancer Treatment

    Standard Treatment Options for Stage 0 Bladder CancerPatients with stage 0 bladder tumors can be cured by a variety of treatments, even though the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder cancer recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for patients with low-grade tumors, it is common among patients with high-grade cancers. One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced-stage disease while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and only 5% progressed.[2] Risk factors for recurrence and progression are the following:[2,3,4,5,6]High-grade disease.Presence of

  9. Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary

    Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the screening of bladder and other urothelial cancers. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made

  10. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

Displaying 11 - 20 of 96 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

Today on WebMD

bladder cancer x-ray
Do you know the warning signs?
man with a doctor
Our health check will steer you in the right direction.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
Lifestyle Tips for Depression Slideshow
SLIDESHOW
Bladder Sparing Cancer Treatment
VIDEO
 
Vitamin D
SLIDESHOW
Pets Improve Your Health
SLIDESHOW
 

WebMD Special Sections